Pembrolizumab and Itacitinib (INCB039110) for NSCLC
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a single center, single arm phase 2 study to establish the safety and efficacy of
itacitinib (also known as INCB039110) administered in combination with pembrolizumab in
patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).